CA Patent

CA2126299C — Parathyroid hormone analogues for the treatment of osteoporosis

Assigned to National Research Council of Canada · Expires 2000-12-12 · 25y expired

What this patent protects

Certain analogues of human parathyroid hormone (hPTH) have been found to be effective for the treatment of osteoporosis, while showing decreased side effects. Analogues showing this effect include all sequences from hPTH-(1-28)-NH2 to hPTH- (1-31)-NH2 and all sequences from [Leu2…

USPTO Abstract

Certain analogues of human parathyroid hormone (hPTH) have been found to be effective for the treatment of osteoporosis, while showing decreased side effects. Analogues showing this effect include all sequences from hPTH-(1-28)-NH2 to hPTH- (1-31)-NH2 and all sequences from [Leu27]-hPTH-(1-28)-NH2 to [Leu27]-hPTH-(1-34)-NH2. Also included are cyclic analogues cyclo(Lys26-Asp30)[Leu27]-hPTH-(1-34)NH2 and cyclo (Lys27-Asp30)- hPTH-(1-34)-NH2. Analogues in the form of the carboxyl terminal amide are particularly effective.

Drugs covered by this patent

Patent Metadata

Patent number
CA2126299C
Jurisdiction
CA
Classification
—
Expires
2000-12-12
Drug substance claim
No
Drug product claim
No
Assignee
National Research Council of Canada
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.